搜尋
Transcode Therapeutics Inc
RNAZ添加自選
6.620USD
+0.410+6.60%
交易中 （美東）報價延遲15分鐘
6.07M總市值
虧損本益比TTM
關於 Transcode Therapeutics Inc 公司
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc簡介
公司代碼RNAZ
公司名稱Transcode Therapeutics Inc
上市日期Apr 28, 2021
CEOCalais (Philippe P)
員工數量7
證券類型Ordinary Share
年結日Apr 28
公司地址6 Liberty Square
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02109
電話18573016857
網址https://www.transcodetherapeutics.com/
公司代碼RNAZ
上市日期Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
常見問題
Transcode Therapeutics Inc的前五大股東是誰？
Transcode Therapeutics Inc的前五大股東如下：Mr. Thomas A. (Tom) Fitzgerald
有多少機構持有Transcode Therapeutics Inc(RNAZ)的股份？
截至2026Q1，共有37家機構持有Transcode Therapeutics Inc的股份，合計持有的股份價值約為77.85K，占公司總股份的8.49% 。與2025Q4相比，機構持股有所增加，增幅為-42306.00。